Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. NRXP
NRXP logo

NRXP News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

NRXP News

NRx and FDA Meeting Advances New Drug Application for NRX-100

Feb 17 2026Newsfilter

NRx Pharmaceuticals Sets Date for 2025 Annual Meeting and Proposal Deadline

Jan 16 2026Globenewswire

NRx Pharmaceuticals Licenses RWE from 70,000 Patients to Support NRX-100 FDA Approval

Jan 14 2026stocktwits

NRX Pharmaceuticals' NRX-100 Receives FDA Fast Track Designation Supported by 70,000 Patient Real-World Evidence

Jan 14 2026Globenewswire

BTIG Raises Hudson Pacific Price Target to $26

Jan 02 2026Benzinga

NRx Pharmaceuticals Repays $5.4 Million Debt, Positions for Accelerated Growth in 2026

Dec 18 2025Globenewswire

NRx Pharmaceuticals Repays $5.4 Million Debt, Positions for Accelerated Growth in 2026

Dec 18 2025Newsfilter

NRx Amends NRX-101 Filing to Enhance Depression Treatment with TMS

Dec 03 2025Globenewswire

NRXP Events

03/09 07:20
HOPE Therapeutics Opens New Clinic in Palm Beach, FL
HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, announced the opening of its Palm Beach, FL clinic location dedicated to the treatment of Depression and PTSD with an interventional psychiatry approach that includes ketamine and other neuroplastic drugs, transcranial magnetic stimulation, and hyperbaric oxygen, combined with physician-led psychotherapy. This clinic location is the most recent addition to HOPE's network of clinics.
03/02 07:20
NRx Pharmaceuticals Appoints Prof. Joshua Brown as Chief Medical Innovation Officer
NRx Pharmaceuticals announced that it has appointed Prof. Joshua Brown, MD, PhD, as its Chief Medical Innovation Officer.

NRXP Monitor News

NRX Pharmaceuticals surges amid market decline

Jan 14 2026

NRXP Earnings Analysis

No Data

No Data

People Also Watch